PHARMOCANN GLOBAL financial statements, including revenue, expenses, profit, and loss
The total revenue of PMCN-M for the last semiannual is 7.78 M ILS, and it's 17.42% higher compared to the previous semiannual. The net income of H2 23 is -2.69 M ILS.